DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Nesina (Alogliptin Benzoate) - Summary

 
 



NESINA SUMMARY

NESINA tablets contain the active ingredient alogliptin, which is a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4).

Monotherapy and Combination Therapy

NESINA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies].

Limitation of Use

NESINA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.


See all Nesina indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Nesina (Alogliptin)

Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. [2014]
with insulin and diet or exercise... CONCLUSIONS: Alogliptin 25 mg/day was effective and well tolerated when added to

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. [2013]
the dipeptidyl peptidase-4 inhibitor alogliptin... CONCLUSION: These analyses have not shown a signal of increased CV risk with

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. [2012]
treatment with glimepiride... CONCLUSIONS: Once-daily alogliptin was effective and generally well tolerated

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. [2011]
inadequate glycaemic control on pioglitazone plus diet/exercise... CONCLUSIONS: Once-daily alogliptin was effective and generally well tolerated

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. [2009]
patients with type 2 diabetes mellitus... CONCLUSION: Alogliptin was effective and well tolerated in the elderly patients

more studies >>

Clinical Trials Related to Nesina (Alogliptin)

Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus [Completed]
The purpose of this study is to determine the pharmacokinetic and safety profile of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.

Efficacy and Safety of Alogliptin and Metformin Fixed-dose Combination in Patients With Type 2 Diabetes [Active, not recruiting]
The purpose of this study is to evaluate the efficacy and safety of alogliptin and metformin fixed-dose combination (FDC) as compared with alogliptin alone or metformin alone on Type 2 Diabetes Mellitus (T2DM).

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes [Completed]
The purpose of the study is to determine the efficacy of alogliptin compared to placebo when given alone or as add-on therapy to metformin or add-on to pioglitazone (with or without metformin).

Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes. [Completed]
The purpose of this study is to compare the efficacy of Alogliptin, once daily (QD), taken by itself and with pioglitazone on postprandial lipid measures in type 2 diabetes.

Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan [Completed]
To evaluate the efficacy and safety of alogliptin administered as an add-on to sulfonylurea (glimepiride) or metformin, once daily (QD), twice daily (BID) or three times daily (TID).

more trials >>


Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015